Eisai Co Ltd (ESALF) Q1 2027 Earnings Call

Investor webinar replay

Replay transcript excerpt

I would like to introduce the speakers today, Mr. Keisuke Naito, COO and Chief Growth Officer. and Mr. Takuya Oyama CFO and Chief IR Officer. First, Mr. Oyama CFO will present the financial results, after which Mr. Naito COO will report on the overall business. Mr. Oyama CFO, please. Thank you very much for gathering to attend this session out of your busy schedule. Let me begin with our financial highlights for the first quarter of fiscal year 2026. Revenue for the first quarter of fiscal year 2026 was 234.3 billion yen, a 15.6% increase from a year earlier. The pharmaceutical business, which is our organic business, grew significantly, achieving double-digit revenue growth. Operating profit reached 24.7 billion yen, a 19.2% increase year-on-year. This double-digit increase was achieved thanks to significant global growth in our major products, Renvima, Deibigo, and Rekembi. Progress towards our 2026 performance forecast is steady, with revenue at 27% and operating profit at 35%. Next slide, please. This page provides details of our consolidated financial results for the first quarter of fiscal year 2026. Revenue increased by 16% to 234.3 billion yen, driven by the growth of our pharmaceutical business, which is centered on our major products 3L, Renvima, Devigo, and Lecambi. Cost of sales was 51.1 billion yen and the cost of sales ratio to revenue was 21.8%. Although the cost ratio increased year-on-year, it was approximately controlled within the planned range through cost reduction efforts. As a result, gross profit reached 183.2 billion yen, up 14.5% year-on-year. R&D expenses increased by 12.7% to 43.7 billion yen reflecting a proactive investment of resources in next-generation key projects. Selling general and administrative expenses increased by 14.6% to ¥11...